Skip to main content

Pointed Interpretation of Clinical Variant Significance

Project description

# Picus Pointed Interpretation of Clinical Variant Significance

## Quick Install * Linux&Mac

> sudo pip3 install picus

  • Windows

> pip install picus

## Example Uses

  • Picus examples

> picus -i input.csv -o output.json

## Evidence Collection Process

### PVS1 * PVS1 null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation codon, single or multiexon deletion) in a gene where LOF is a known mechanism of disease.

#### Status * Implemented

#### Resources * LoF genes defined by Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). * Null variants defined as HIGH IMPACT by https://www.ensembl.org/info/genome/variation/prediction/predicted_data.html

#### Conditions * “gene_symbol” is in LoF gene list. * “transcript_consequence_terms” is high impact.

#### Shortcomings * LoF gene list is only predictive and may be missing some actual LoF genes. * No checks for multiexon deletion.

#### Pathogenic Strong

### PS1 * Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.

#### Status * Implemented

#### Resources * Clinvar xml (ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/)

#### Annotation Steps 1. Clinvar data is parsed using https://github.com/barslmn/clinvar. 2. Sample data and clinvar data is merged based on columns “CHR” and “POS”. 3. Clinvar feature columns “ALT”, “hgvsp”, and “clinical_significance” added to original annotation.

#### Conditions 1. “clinical_significance” is pathogenic. 2. Sample “hgvsp” and later added clinvar “hgvsp” changes are the same. 3. Sample “ALT” and clinvar “ALT” are different.

#### Shortcomings

### PS2 * De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.

#### Status * Not Checked

#### Resources

#### Conditions

#### Shortcomings

### PS3 * Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product

#### Status * Not Checked

#### Resources

#### Conditions

#### Shortcomings

### PS4 * The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls

#### Status * Implemented

#### Resources * https://github.com/WGLab/InterVar/blob/master/intervardb/PS4.variants.hg19

#### Conditions 1. “id” is in id list.

#### Shortcomings 1. No idea how the source is made.

#### Pathogenic Moderate

### PM1 * Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation

#### Status * Planned.

#### Resources

#### Conditions

#### Shortcomings

### PM2 * Absent from controls (or at extremely low frequency if recessive) (Table 6) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium

#### Status * Implemented

#### Resources * VEP

#### Conditions * “gnomad” less than 0.001.

#### Shortcomings

### PM3 * For recessive disorders, detected in trans with a pathogenic variant

#### Status * Not Checked

#### Resources

#### Conditions

#### Shortcomings

### PM4 * Protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-loss variants

#### Status * Implemented

#### Resources * VEP

#### Conditions * “transcript_consequence_terms” is “inframe_insertion”, “inframe_deletion”, or “stop_lost”.

#### Shortcomings * No checks for repeat regions.

### PM5 * Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before

#### Status

#### Resources

#### Conditions

#### Shortcomings

### PM6 * Assumed de novo, but without confirmation of paternity and maternity #### Status

#### Resources

#### Conditions

#### Shortcomings

#### Pathogenic Supporting

### PP1 * Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease #### Status

#### Resources

#### Conditions

#### Shortcomings

### PP2 * Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease #### Status

#### Resources

#### Conditions

#### Shortcomings

### PP3 * Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.) #### Status

#### Resources

#### Conditions

#### Shortcomings

### PP4 * Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology #### Status

#### Resources

#### Conditions

#### Shortcomings

### PP5 * Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation #### Status

#### Resources

#### Conditions

#### Shortcomings

### Benign

#### Benign Stand-alone

### BA1 * Allele frequency is >5% in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium #### Status

#### Resources

#### Conditions

#### Shortcomings

### Benign Strong

### BS1 * Allele frequency is greater than expected for disorder #### Status

#### Resources

#### Conditions

#### Shortcomings

### BS2 * Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age #### Status

#### Resources

#### Conditions

#### Shortcomings

### BS3 * Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing #### Status

#### Resources

#### Conditions

#### Shortcomings

### BS4 * Lack of segregation in affected members of a family #### Status

#### Resources

#### Conditions

#### Shortcomings

### Benign Supporting

### BP1 * Missense variant in a gene for which primarily truncating variants are known to cause disease #### Status

#### Resources

#### Conditions

#### Shortcomings

### BP2 * Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern #### Status

#### Resources

#### Conditions

#### Shortcomings

### BP3 * In-frame deletions/insertions in a repetitive region without a known function #### Status

#### Resources

#### Conditions

#### Shortcomings

### BP4 * Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.) #### Status

#### Resources

#### Conditions

#### Shortcomings

### BP5 * Variant found in a case with an alternate molecular basis for disease #### Status

#### Resources

#### Conditions

#### Shortcomings

### BP6 * Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation #### Status

#### Resources

#### Conditions

#### Shortcomings

### BP7 * A synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved #### Status

#### Resources

#### Conditions

#### Shortcomings

Project details


Download files

Download the file for your platform. If you're not sure which to choose, learn more about installing packages.

Files for picus, version 0.0.2
Filename, size File type Python version Upload date Hashes
Filename, size picus-0.0.2-py3-none-any.whl (6.8 MB) File type Wheel Python version py3 Upload date Hashes View

Supported by

AWS AWS Cloud computing Datadog Datadog Monitoring DigiCert DigiCert EV certificate Facebook / Instagram Facebook / Instagram PSF Sponsor Fastly Fastly CDN Google Google Object Storage and Download Analytics Microsoft Microsoft PSF Sponsor Pingdom Pingdom Monitoring Salesforce Salesforce PSF Sponsor Sentry Sentry Error logging StatusPage StatusPage Status page